AustralieFrV1, PascalFrancis, Curation, bibRecord, 005012

First Serial Assessment at 6 Months and 2 Years of the Second Generation of Absorb Everolimus-Eluting Bioresorbable Vascular Scaffold: A Multi-Imaging Modality Study

Identifieur interne : 005012 ( PascalFrancis/Curation ); précédent : 005011; suivant : 005013

First Serial Assessment at 6 Months and 2 Years of the Second Generation of Absorb Everolimus-Eluting Bioresorbable Vascular Scaffold: A Multi-Imaging Modality Study

Auteurs : John A. Ormiston [Nouvelle-Zélande] ; Patrick W. Serruys [Pays-Bas] ; Yoshinobu Onuma [Pays-Bas] ; Robert-Jan Van Geuns [Pays-Bas] ; Bernard De Bruyne [Belgique] ; Dariusz Dudek [Pologne] ; Leif Thuesen [Danemark] ; Pieter C. Smits [Pays-Bas] ; Bernard Chevalier [France] ; Dougal Mcclean [Nouvelle-Zélande] ; Jacques Koolen [Pays-Bas] ; Stephan Windecker [Suisse] ; Robert Whitbourn [Australie] ; Ian Meredith [Australie] ; Cecile Dorange [Belgique] ; Susan Veldhof [Belgique] ; Karine Miquel Hebert [Belgique] ; Richard Rapoza [États-Unis] ; Hector M. Garcia-Garcia [Pays-Bas]

Source :

Circulation. Cardiovascular interventions [ 1941-7640 ] ; 2012.

RBID : Pascal:12-0423421

Descripteurs français

Pascal (Inist)
- Thrombose, Cardiopathie coronaire, Resténose, Pronostic, Etude multicentrique, Homme, Coronarographie, Ultrason, Tomographie en cohérence optique, Complication, Représentation tridimensionnelle, Préopératoire, Suture chirurgicale, Hémodialyse, Imagerie RMN, Long terme, Fixation agrafe, Objet test, Artère, Compliance(volume pression).
Wicri :
- topic : Homme.

English descriptors

KwdEn :
- Artery, Complication, Coronary arteriography, Coronary heart disease, Hemodialysis, Human, Long term, Multicenter study, Nuclear magnetic resonance imaging, Optical coherence tomography, Preoperative, Prognosis, Restenosis, Stapling, Suturation, Test object, Three dimensional representation, Thrombosis, Ultrasound.

Abstract

Background-Nonserial observations have shown this bioresorbable scaffold to have no signs of area reduction at 6 months and recovery of vasomotion at 1 year. Serial observations at 6 months and 2 years have to confirm the absence of late restenosis or unfavorable imaging outcomes. Methods and Results-The ABSORB trial is a multicenter single-arm trial assessing the safety and performance of an everolimus-eluting bioresorbable vascular scaffold. Forty-five patients underwent serial invasive imaging, such as quantitative coronary angiography, intravascular ultrasound, and optical coherence tomography at 6 and 24 months of follow-up. From 6 to 24 months, late luminal loss increased from 0.16±0.18 to 0.27±0.20 mm on quantitative coronary angiography, with an increase in neointima of 0.68±0.43 mm² on optical coherence tomography and 0.17±0.26 mm² on intravascular ultrasound. Struts still recognizable on optical coherence tomography at 2 years showed 99% of neointimal coverage with optical and ultrasonic signs of bioresorption accompanied by increase in mean scaffold area compared with baseline (0.54±1.09 mm² on intravascular ultrasound, P=0.003 and 0.77±1.33 m² on optical coherence tomography, P=0.016). Two-year major adverse cardiac event rate was 6.8% without any scaffold thrombosis. Conclusions-This serial analysis of the second generation of the everolimus-eluting bioresorbable vascular scaffold confirmed, at medium term, the safety and efficacy of the new device.

A01	`01`	`1`		`@0 1941-7640`
A03		`1`		`@0 Circ. Cardiovasc. interv.`
A05				`@2 5`
A06				`@2 5`
A08	`01`	`1`	`ENG`	`@1 First Serial Assessment at 6 Months and 2 Years of the Second Generation of Absorb Everolimus-Eluting Bioresorbable Vascular Scaffold: A Multi-Imaging Modality Study`
A11	`01`	`1`		`@1 ORMISTON (John A.)`
A11	`02`	`1`		`@1 SERRUYS (Patrick W.)`
A11	`03`	`1`		`@1 ONUMA (Yoshinobu)`
A11	`04`	`1`		`@1 GEUNS (Robert-Jan Van)`
A11	`05`	`1`		`@1 DE BRUYNE (Bernard)`
A11	`06`	`1`		`@1 DUDEK (Dariusz)`
A11	`07`	`1`		`@1 THUESEN (Leif)`
A11	`08`	`1`		`@1 SMITS (Pieter C.)`
A11	`09`	`1`		`@1 CHEVALIER (Bernard)`
A11	`10`	`1`		`@1 MCCLEAN (Dougal)`
A11	`11`	`1`		`@1 KOOLEN (Jacques)`
A11	`12`	`1`		`@1 WINDECKER (Stephan)`
A11	`13`	`1`		`@1 WHITBOURN (Robert)`
A11	`14`	`1`		`@1 MEREDITH (Ian)`
A11	`15`	`1`		`@1 DORANGE (Cecile)`
A11	`16`	`1`		`@1 VELDHOF (Susan)`
A11	`17`	`1`		`@1 MIQUEL HEBERT (Karine)`
A11	`18`	`1`		`@1 RAPOZA (Richard)`
A11	`19`	`1`		`@1 GARCIA-GARCIA (Hector M.)`
A14	`01`			`@1 Auckland City Hospital @2 Auckland @3 NZL @Z 1 aut.`
A14	`02`			`@1 ThoraxCenter, Erasmus Medical Center @2 Rotterdam @3 NLD @Z 2 aut. @Z 3 aut. @Z 4 aut.`
A14	`03`			`@1 Cardiovascular Center @2 Aalst @3 BEL @Z 5 aut.`
A14	`04`			`@1 Jagiellonian University @2 Krakow @3 POL @Z 6 aut.`
A14	`05`			`@1 Skejby Sygehus University Hospital @2 Aarhus @3 DNK @Z 7 aut.`
A14	`06`			`@1 Maasstad Hospital @2 Rotterdam @3 NLD @Z 8 aut.`
A14	`07`			`@1 Institut Jacques Cartier @2 Massy @3 FRA @Z 9 aut.`
A14	`08`			`@1 Christchurch Hospital @2 Christchurch @3 NZL @Z 10 aut.`
A14	`09`			`@1 Catharina Hospital @2 Eindhoven @3 NLD @Z 11 aut.`
A14	`10`			`@1 Bern University Hospital @2 Bern @3 CHE @Z 12 aut.`
A14	`11`			`@1 St Vincent's Hospital @2 Fitzroy @3 AUS @Z 13 aut.`
A14	`12`			`@1 Monash Cardiovascular Research Centre @2 Melbourne @3 AUS @Z 14 aut.`
A14	`13`			`@1 Abbott Vascular @2 Diegem @3 BEL @Z 15 aut. @Z 16 aut. @Z 17 aut.`
A14	`14`			`@1 Abbott Vascular @2 Santa Clara, CA @3 USA @Z 18 aut.`
A14	`15`			`@1 Cardialysis @2 Rotterdam @3 NLD @Z 19 aut.`
A20				`@1 620-632`
A21				`@1 2012`
A23	`01`			`@0 ENG`
A43	`01`			`@1 INIST @2 28045 @5 354000502078030020`
A44				`@0 0000 @1 © 2012 INIST-CNRS. All rights reserved.`
A45				`@0 45 ref.`
A47	`01`	`1`		`@0 12-0423421`
A60				`@1 P`
A61				`@0 A`
A64	`01`	`1`		`@0 Circulation. Cardiovascular interventions`
A66	`01`			`@0 USA`
C01	`01`		`ENG`	@0 Background-Nonserial observations have shown this bioresorbable scaffold to have no signs of area reduction at 6 months and recovery of vasomotion at 1 year. Serial observations at 6 months and 2 years have to confirm the absence of late restenosis or unfavorable imaging outcomes. Methods and Results-The ABSORB trial is a multicenter single-arm trial assessing the safety and performance of an everolimus-eluting bioresorbable vascular scaffold. Forty-five patients underwent serial invasive imaging, such as quantitative coronary angiography, intravascular ultrasound, and optical coherence tomography at 6 and 24 months of follow-up. From 6 to 24 months, late luminal loss increased from 0.16±0.18 to 0.27±0.20 mm on quantitative coronary angiography, with an increase in neointima of 0.68±0.43 mm² on optical coherence tomography and 0.17±0.26 mm² on intravascular ultrasound. Struts still recognizable on optical coherence tomography at 2 years showed 99% of neointimal coverage with optical and ultrasonic signs of bioresorption accompanied by increase in mean scaffold area compared with baseline (0.54±1.09 mm² on intravascular ultrasound, P=0.003 and 0.77±1.33 m² on optical coherence tomography, P=0.016). Two-year major adverse cardiac event rate was 6.8% without any scaffold thrombosis. Conclusions-This serial analysis of the second generation of the everolimus-eluting bioresorbable vascular scaffold confirmed, at medium term, the safety and efficacy of the new device.
C02	`01`	`X`		`@0 002B25F`
C02	`02`	`X`		`@0 002B27B03`
C02	`03`	`X`		`@0 002B25G03`
C03	`01`	`X`	`FRE`	`@0 Thrombose @5 01`
C03	`01`	`X`	`ENG`	`@0 Thrombosis @5 01`
C03	`01`	`X`	`SPA`	`@0 Trombosis @5 01`
C03	`02`	`X`	`FRE`	`@0 Cardiopathie coronaire @5 02`
C03	`02`	`X`	`ENG`	`@0 Coronary heart disease @5 02`
C03	`02`	`X`	`SPA`	`@0 Cardiopatía coronaria @5 02`
C03	`03`	`X`	`FRE`	`@0 Resténose @5 09`
C03	`03`	`X`	`ENG`	`@0 Restenosis @5 09`
C03	`03`	`X`	`SPA`	`@0 Reestenosis @5 09`
C03	`04`	`X`	`FRE`	`@0 Pronostic @5 10`
C03	`04`	`X`	`ENG`	`@0 Prognosis @5 10`
C03	`04`	`X`	`SPA`	`@0 Pronóstico @5 10`
C03	`05`	`X`	`FRE`	`@0 Etude multicentrique @5 11`
C03	`05`	`X`	`ENG`	`@0 Multicenter study @5 11`
C03	`05`	`X`	`SPA`	`@0 Estudio multicéntrico @5 11`
C03	`06`	`X`	`FRE`	`@0 Homme @5 12`
C03	`06`	`X`	`ENG`	`@0 Human @5 12`
C03	`06`	`X`	`SPA`	`@0 Hombre @5 12`
C03	`07`	`X`	`FRE`	`@0 Coronarographie @5 13`
C03	`07`	`X`	`ENG`	`@0 Coronary arteriography @5 13`
C03	`07`	`X`	`SPA`	`@0 Coronarografía @5 13`
C03	`08`	`X`	`FRE`	`@0 Ultrason @5 14`
C03	`08`	`X`	`ENG`	`@0 Ultrasound @5 14`
C03	`08`	`X`	`SPA`	`@0 Ultrasonido @5 14`
C03	`09`	`X`	`FRE`	`@0 Tomographie en cohérence optique @5 15`
C03	`09`	`X`	`ENG`	`@0 Optical coherence tomography @5 15`
C03	`09`	`X`	`SPA`	`@0 Tomógrafo óptico de coherencia @5 15`
C03	`10`	`X`	`FRE`	`@0 Complication @5 16`
C03	`10`	`X`	`ENG`	`@0 Complication @5 16`
C03	`10`	`X`	`SPA`	`@0 Complicación @5 16`
C03	`11`	`X`	`FRE`	`@0 Représentation tridimensionnelle @5 17`
C03	`11`	`X`	`ENG`	`@0 Three dimensional representation @5 17`
C03	`11`	`X`	`SPA`	`@0 Representación tridimensional @5 17`
C03	`12`	`X`	`FRE`	`@0 Préopératoire @5 18`
C03	`12`	`X`	`ENG`	`@0 Preoperative @5 18`
C03	`12`	`X`	`SPA`	`@0 Preoperatorio @5 18`
C03	`13`	`X`	`FRE`	`@0 Suture chirurgicale @5 19`
C03	`13`	`X`	`ENG`	`@0 Suturation @5 19`
C03	`13`	`X`	`SPA`	`@0 Sutura quirúrgica @5 19`
C03	`14`	`X`	`FRE`	`@0 Hémodialyse @5 20`
C03	`14`	`X`	`ENG`	`@0 Hemodialysis @5 20`
C03	`14`	`X`	`SPA`	`@0 Hemodiálisis @5 20`
C03	`15`	`X`	`FRE`	`@0 Imagerie RMN @5 21`
C03	`15`	`X`	`ENG`	`@0 Nuclear magnetic resonance imaging @5 21`
C03	`15`	`X`	`SPA`	`@0 Imaginería RMN @5 21`
C03	`16`	`X`	`FRE`	`@0 Long terme @5 22`
C03	`16`	`X`	`ENG`	`@0 Long term @5 22`
C03	`16`	`X`	`SPA`	`@0 Largo plazo @5 22`
C03	`17`	`X`	`FRE`	`@0 Fixation agrafe @5 23`
C03	`17`	`X`	`ENG`	`@0 Stapling @5 23`
C03	`17`	`X`	`SPA`	`@0 Fijación con grapa @5 23`
C03	`18`	`X`	`FRE`	`@0 Objet test @5 24`
C03	`18`	`X`	`ENG`	`@0 Test object @5 24`
C03	`18`	`X`	`SPA`	`@0 Objeto prueba @5 24`
C03	`19`	`X`	`FRE`	`@0 Artère @5 25`
C03	`19`	`X`	`ENG`	`@0 Artery @5 25`
C03	`19`	`X`	`SPA`	`@0 Arteria @5 25`
C03	`20`	`X`	`FRE`	`@0 Compliance(volume pression) @4 INC @5 86`
C07	`01`	`X`	`FRE`	`@0 Pathologie de l'appareil circulatoire @5 37`
C07	`01`	`X`	`ENG`	`@0 Cardiovascular disease @5 37`
C07	`01`	`X`	`SPA`	`@0 Aparato circulatorio patología @5 37`
C07	`02`	`X`	`FRE`	`@0 Pathologie des vaisseaux sanguins @5 38`
C07	`02`	`X`	`ENG`	`@0 Vascular disease @5 38`
C07	`02`	`X`	`SPA`	`@0 Vaso sanguíneo patología @5 38`
N21				`@1 331`
N44	`01`			`@1 OTO`
N82				`@1 OTO`

Links toward previous steps (curation, corpus...)

to stream PascalFrancis, to step Corpus: Pour aller vers cette notice dans l'étape Curation :000F09

Links to Exploration step

Pascal:12-0423421

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">First Serial Assessment at 6 Months and 2 Years of the Second Generation of Absorb Everolimus-Eluting Bioresorbable Vascular Scaffold: A Multi-Imaging Modality Study</title>
<author><name sortKey="Ormiston, John A" sort="Ormiston, John A" uniqKey="Ormiston J" first="John A." last="Ormiston">John A. Ormiston</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Auckland City Hospital</s1>
<s2>Auckland</s2>
<s3>NZL</s3>
<sZ>1 aut.</sZ>
</inist:fA14>
<country>Nouvelle-Zélande</country>
</affiliation>
</author>
<author><name sortKey="Serruys, Patrick W" sort="Serruys, Patrick W" uniqKey="Serruys P" first="Patrick W." last="Serruys">Patrick W. Serruys</name>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>ThoraxCenter, Erasmus Medical Center</s1>
<s2>Rotterdam</s2>
<s3>NLD</s3>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
<country>Pays-Bas</country>
</affiliation>
</author>
<author><name sortKey="Onuma, Yoshinobu" sort="Onuma, Yoshinobu" uniqKey="Onuma Y" first="Yoshinobu" last="Onuma">Yoshinobu Onuma</name>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>ThoraxCenter, Erasmus Medical Center</s1>
<s2>Rotterdam</s2>
<s3>NLD</s3>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
<country>Pays-Bas</country>
</affiliation>
</author>
<author><name sortKey="Geuns, Robert Jan Van" sort="Geuns, Robert Jan Van" uniqKey="Geuns R" first="Robert-Jan Van" last="Geuns">Robert-Jan Van Geuns</name>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>ThoraxCenter, Erasmus Medical Center</s1>
<s2>Rotterdam</s2>
<s3>NLD</s3>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
<country>Pays-Bas</country>
</affiliation>
</author>
<author><name sortKey="De Bruyne, Bernard" sort="De Bruyne, Bernard" uniqKey="De Bruyne B" first="Bernard" last="De Bruyne">Bernard De Bruyne</name>
<affiliation wicri:level="1"><inist:fA14 i1="03"><s1>Cardiovascular Center</s1>
<s2>Aalst</s2>
<s3>BEL</s3>
<sZ>5 aut.</sZ>
</inist:fA14>
<country>Belgique</country>
</affiliation>
</author>
<author><name sortKey="Dudek, Dariusz" sort="Dudek, Dariusz" uniqKey="Dudek D" first="Dariusz" last="Dudek">Dariusz Dudek</name>
<affiliation wicri:level="1"><inist:fA14 i1="04"><s1>Jagiellonian University</s1>
<s2>Krakow</s2>
<s3>POL</s3>
<sZ>6 aut.</sZ>
</inist:fA14>
<country>Pologne</country>
</affiliation>
</author>
<author><name sortKey="Thuesen, Leif" sort="Thuesen, Leif" uniqKey="Thuesen L" first="Leif" last="Thuesen">Leif Thuesen</name>
<affiliation wicri:level="1"><inist:fA14 i1="05"><s1>Skejby Sygehus University Hospital</s1>
<s2>Aarhus</s2>
<s3>DNK</s3>
<sZ>7 aut.</sZ>
</inist:fA14>
<country>Danemark</country>
</affiliation>
</author>
<author><name sortKey="Smits, Pieter C" sort="Smits, Pieter C" uniqKey="Smits P" first="Pieter C." last="Smits">Pieter C. Smits</name>
<affiliation wicri:level="1"><inist:fA14 i1="06"><s1>Maasstad Hospital</s1>
<s2>Rotterdam</s2>
<s3>NLD</s3>
<sZ>8 aut.</sZ>
</inist:fA14>
<country>Pays-Bas</country>
</affiliation>
</author>
<author><name sortKey="Chevalier, Bernard" sort="Chevalier, Bernard" uniqKey="Chevalier B" first="Bernard" last="Chevalier">Bernard Chevalier</name>
<affiliation wicri:level="1"><inist:fA14 i1="07"><s1>Institut Jacques Cartier</s1>
<s2>Massy</s2>
<s3>FRA</s3>
<sZ>9 aut.</sZ>
</inist:fA14>
<country>France</country>
</affiliation>
</author>
<author><name sortKey="Mcclean, Dougal" sort="Mcclean, Dougal" uniqKey="Mcclean D" first="Dougal" last="Mcclean">Dougal Mcclean</name>
<affiliation wicri:level="1"><inist:fA14 i1="08"><s1>Christchurch Hospital</s1>
<s2>Christchurch</s2>
<s3>NZL</s3>
<sZ>10 aut.</sZ>
</inist:fA14>
<country>Nouvelle-Zélande</country>
</affiliation>
</author>
<author><name sortKey="Koolen, Jacques" sort="Koolen, Jacques" uniqKey="Koolen J" first="Jacques" last="Koolen">Jacques Koolen</name>
<affiliation wicri:level="1"><inist:fA14 i1="09"><s1>Catharina Hospital</s1>
<s2>Eindhoven</s2>
<s3>NLD</s3>
<sZ>11 aut.</sZ>
</inist:fA14>
<country>Pays-Bas</country>
</affiliation>
</author>
<author><name sortKey="Windecker, Stephan" sort="Windecker, Stephan" uniqKey="Windecker S" first="Stephan" last="Windecker">Stephan Windecker</name>
<affiliation wicri:level="1"><inist:fA14 i1="10"><s1>Bern University Hospital</s1>
<s2>Bern</s2>
<s3>CHE</s3>
<sZ>12 aut.</sZ>
</inist:fA14>
<country>Suisse</country>
</affiliation>
</author>
<author><name sortKey="Whitbourn, Robert" sort="Whitbourn, Robert" uniqKey="Whitbourn R" first="Robert" last="Whitbourn">Robert Whitbourn</name>
<affiliation wicri:level="1"><inist:fA14 i1="11"><s1>St Vincent's Hospital</s1>
<s2>Fitzroy</s2>
<s3>AUS</s3>
<sZ>13 aut.</sZ>
</inist:fA14>
<country>Australie</country>
</affiliation>
</author>
<author><name sortKey="Meredith, Ian" sort="Meredith, Ian" uniqKey="Meredith I" first="Ian" last="Meredith">Ian Meredith</name>
<affiliation wicri:level="1"><inist:fA14 i1="12"><s1>Monash Cardiovascular Research Centre</s1>
<s2>Melbourne</s2>
<s3>AUS</s3>
<sZ>14 aut.</sZ>
</inist:fA14>
<country>Australie</country>
</affiliation>
</author>
<author><name sortKey="Dorange, Cecile" sort="Dorange, Cecile" uniqKey="Dorange C" first="Cecile" last="Dorange">Cecile Dorange</name>
<affiliation wicri:level="1"><inist:fA14 i1="13"><s1>Abbott Vascular</s1>
<s2>Diegem</s2>
<s3>BEL</s3>
<sZ>15 aut.</sZ>
<sZ>16 aut.</sZ>
<sZ>17 aut.</sZ>
</inist:fA14>
<country>Belgique</country>
</affiliation>
</author>
<author><name sortKey="Veldhof, Susan" sort="Veldhof, Susan" uniqKey="Veldhof S" first="Susan" last="Veldhof">Susan Veldhof</name>
<affiliation wicri:level="1"><inist:fA14 i1="13"><s1>Abbott Vascular</s1>
<s2>Diegem</s2>
<s3>BEL</s3>
<sZ>15 aut.</sZ>
<sZ>16 aut.</sZ>
<sZ>17 aut.</sZ>
</inist:fA14>
<country>Belgique</country>
</affiliation>
</author>
<author><name sortKey="Miquel Hebert, Karine" sort="Miquel Hebert, Karine" uniqKey="Miquel Hebert K" first="Karine" last="Miquel Hebert">Karine Miquel Hebert</name>
<affiliation wicri:level="1"><inist:fA14 i1="13"><s1>Abbott Vascular</s1>
<s2>Diegem</s2>
<s3>BEL</s3>
<sZ>15 aut.</sZ>
<sZ>16 aut.</sZ>
<sZ>17 aut.</sZ>
</inist:fA14>
<country>Belgique</country>
</affiliation>
</author>
<author><name sortKey="Rapoza, Richard" sort="Rapoza, Richard" uniqKey="Rapoza R" first="Richard" last="Rapoza">Richard Rapoza</name>
<affiliation wicri:level="1"><inist:fA14 i1="14"><s1>Abbott Vascular</s1>
<s2>Santa Clara, CA</s2>
<s3>USA</s3>
<sZ>18 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
</affiliation>
</author>
<author><name sortKey="Garcia Garcia, Hector M" sort="Garcia Garcia, Hector M" uniqKey="Garcia Garcia H" first="Hector M." last="Garcia-Garcia">Hector M. Garcia-Garcia</name>
<affiliation wicri:level="1"><inist:fA14 i1="15"><s1>Cardialysis</s1>
<s2>Rotterdam</s2>
<s3>NLD</s3>
<sZ>19 aut.</sZ>
</inist:fA14>
<country>Pays-Bas</country>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">INIST</idno>
<idno type="inist">12-0423421</idno>
<date when="2012">2012</date>
<idno type="stanalyst">PASCAL 12-0423421 INIST</idno>
<idno type="RBID">Pascal:12-0423421</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">000F09</idno>
<idno type="wicri:Area/PascalFrancis/Curation">005012</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">First Serial Assessment at 6 Months and 2 Years of the Second Generation of Absorb Everolimus-Eluting Bioresorbable Vascular Scaffold: A Multi-Imaging Modality Study</title>
<author><name sortKey="Ormiston, John A" sort="Ormiston, John A" uniqKey="Ormiston J" first="John A." last="Ormiston">John A. Ormiston</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Auckland City Hospital</s1>
<s2>Auckland</s2>
<s3>NZL</s3>
<sZ>1 aut.</sZ>
</inist:fA14>
<country>Nouvelle-Zélande</country>
</affiliation>
</author>
<author><name sortKey="Serruys, Patrick W" sort="Serruys, Patrick W" uniqKey="Serruys P" first="Patrick W." last="Serruys">Patrick W. Serruys</name>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>ThoraxCenter, Erasmus Medical Center</s1>
<s2>Rotterdam</s2>
<s3>NLD</s3>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
<country>Pays-Bas</country>
</affiliation>
</author>
<author><name sortKey="Onuma, Yoshinobu" sort="Onuma, Yoshinobu" uniqKey="Onuma Y" first="Yoshinobu" last="Onuma">Yoshinobu Onuma</name>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>ThoraxCenter, Erasmus Medical Center</s1>
<s2>Rotterdam</s2>
<s3>NLD</s3>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
<country>Pays-Bas</country>
</affiliation>
</author>
<author><name sortKey="Geuns, Robert Jan Van" sort="Geuns, Robert Jan Van" uniqKey="Geuns R" first="Robert-Jan Van" last="Geuns">Robert-Jan Van Geuns</name>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>ThoraxCenter, Erasmus Medical Center</s1>
<s2>Rotterdam</s2>
<s3>NLD</s3>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
<country>Pays-Bas</country>
</affiliation>
</author>
<author><name sortKey="De Bruyne, Bernard" sort="De Bruyne, Bernard" uniqKey="De Bruyne B" first="Bernard" last="De Bruyne">Bernard De Bruyne</name>
<affiliation wicri:level="1"><inist:fA14 i1="03"><s1>Cardiovascular Center</s1>
<s2>Aalst</s2>
<s3>BEL</s3>
<sZ>5 aut.</sZ>
</inist:fA14>
<country>Belgique</country>
</affiliation>
</author>
<author><name sortKey="Dudek, Dariusz" sort="Dudek, Dariusz" uniqKey="Dudek D" first="Dariusz" last="Dudek">Dariusz Dudek</name>
<affiliation wicri:level="1"><inist:fA14 i1="04"><s1>Jagiellonian University</s1>
<s2>Krakow</s2>
<s3>POL</s3>
<sZ>6 aut.</sZ>
</inist:fA14>
<country>Pologne</country>
</affiliation>
</author>
<author><name sortKey="Thuesen, Leif" sort="Thuesen, Leif" uniqKey="Thuesen L" first="Leif" last="Thuesen">Leif Thuesen</name>
<affiliation wicri:level="1"><inist:fA14 i1="05"><s1>Skejby Sygehus University Hospital</s1>
<s2>Aarhus</s2>
<s3>DNK</s3>
<sZ>7 aut.</sZ>
</inist:fA14>
<country>Danemark</country>
</affiliation>
</author>
<author><name sortKey="Smits, Pieter C" sort="Smits, Pieter C" uniqKey="Smits P" first="Pieter C." last="Smits">Pieter C. Smits</name>
<affiliation wicri:level="1"><inist:fA14 i1="06"><s1>Maasstad Hospital</s1>
<s2>Rotterdam</s2>
<s3>NLD</s3>
<sZ>8 aut.</sZ>
</inist:fA14>
<country>Pays-Bas</country>
</affiliation>
</author>
<author><name sortKey="Chevalier, Bernard" sort="Chevalier, Bernard" uniqKey="Chevalier B" first="Bernard" last="Chevalier">Bernard Chevalier</name>
<affiliation wicri:level="1"><inist:fA14 i1="07"><s1>Institut Jacques Cartier</s1>
<s2>Massy</s2>
<s3>FRA</s3>
<sZ>9 aut.</sZ>
</inist:fA14>
<country>France</country>
</affiliation>
</author>
<author><name sortKey="Mcclean, Dougal" sort="Mcclean, Dougal" uniqKey="Mcclean D" first="Dougal" last="Mcclean">Dougal Mcclean</name>
<affiliation wicri:level="1"><inist:fA14 i1="08"><s1>Christchurch Hospital</s1>
<s2>Christchurch</s2>
<s3>NZL</s3>
<sZ>10 aut.</sZ>
</inist:fA14>
<country>Nouvelle-Zélande</country>
</affiliation>
</author>
<author><name sortKey="Koolen, Jacques" sort="Koolen, Jacques" uniqKey="Koolen J" first="Jacques" last="Koolen">Jacques Koolen</name>
<affiliation wicri:level="1"><inist:fA14 i1="09"><s1>Catharina Hospital</s1>
<s2>Eindhoven</s2>
<s3>NLD</s3>
<sZ>11 aut.</sZ>
</inist:fA14>
<country>Pays-Bas</country>
</affiliation>
</author>
<author><name sortKey="Windecker, Stephan" sort="Windecker, Stephan" uniqKey="Windecker S" first="Stephan" last="Windecker">Stephan Windecker</name>
<affiliation wicri:level="1"><inist:fA14 i1="10"><s1>Bern University Hospital</s1>
<s2>Bern</s2>
<s3>CHE</s3>
<sZ>12 aut.</sZ>
</inist:fA14>
<country>Suisse</country>
</affiliation>
</author>
<author><name sortKey="Whitbourn, Robert" sort="Whitbourn, Robert" uniqKey="Whitbourn R" first="Robert" last="Whitbourn">Robert Whitbourn</name>
<affiliation wicri:level="1"><inist:fA14 i1="11"><s1>St Vincent's Hospital</s1>
<s2>Fitzroy</s2>
<s3>AUS</s3>
<sZ>13 aut.</sZ>
</inist:fA14>
<country>Australie</country>
</affiliation>
</author>
<author><name sortKey="Meredith, Ian" sort="Meredith, Ian" uniqKey="Meredith I" first="Ian" last="Meredith">Ian Meredith</name>
<affiliation wicri:level="1"><inist:fA14 i1="12"><s1>Monash Cardiovascular Research Centre</s1>
<s2>Melbourne</s2>
<s3>AUS</s3>
<sZ>14 aut.</sZ>
</inist:fA14>
<country>Australie</country>
</affiliation>
</author>
<author><name sortKey="Dorange, Cecile" sort="Dorange, Cecile" uniqKey="Dorange C" first="Cecile" last="Dorange">Cecile Dorange</name>
<affiliation wicri:level="1"><inist:fA14 i1="13"><s1>Abbott Vascular</s1>
<s2>Diegem</s2>
<s3>BEL</s3>
<sZ>15 aut.</sZ>
<sZ>16 aut.</sZ>
<sZ>17 aut.</sZ>
</inist:fA14>
<country>Belgique</country>
</affiliation>
</author>
<author><name sortKey="Veldhof, Susan" sort="Veldhof, Susan" uniqKey="Veldhof S" first="Susan" last="Veldhof">Susan Veldhof</name>
<affiliation wicri:level="1"><inist:fA14 i1="13"><s1>Abbott Vascular</s1>
<s2>Diegem</s2>
<s3>BEL</s3>
<sZ>15 aut.</sZ>
<sZ>16 aut.</sZ>
<sZ>17 aut.</sZ>
</inist:fA14>
<country>Belgique</country>
</affiliation>
</author>
<author><name sortKey="Miquel Hebert, Karine" sort="Miquel Hebert, Karine" uniqKey="Miquel Hebert K" first="Karine" last="Miquel Hebert">Karine Miquel Hebert</name>
<affiliation wicri:level="1"><inist:fA14 i1="13"><s1>Abbott Vascular</s1>
<s2>Diegem</s2>
<s3>BEL</s3>
<sZ>15 aut.</sZ>
<sZ>16 aut.</sZ>
<sZ>17 aut.</sZ>
</inist:fA14>
<country>Belgique</country>
</affiliation>
</author>
<author><name sortKey="Rapoza, Richard" sort="Rapoza, Richard" uniqKey="Rapoza R" first="Richard" last="Rapoza">Richard Rapoza</name>
<affiliation wicri:level="1"><inist:fA14 i1="14"><s1>Abbott Vascular</s1>
<s2>Santa Clara, CA</s2>
<s3>USA</s3>
<sZ>18 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
</affiliation>
</author>
<author><name sortKey="Garcia Garcia, Hector M" sort="Garcia Garcia, Hector M" uniqKey="Garcia Garcia H" first="Hector M." last="Garcia-Garcia">Hector M. Garcia-Garcia</name>
<affiliation wicri:level="1"><inist:fA14 i1="15"><s1>Cardialysis</s1>
<s2>Rotterdam</s2>
<s3>NLD</s3>
<sZ>19 aut.</sZ>
</inist:fA14>
<country>Pays-Bas</country>
</affiliation>
</author>
</analytic>
<series><title level="j" type="main">Circulation. Cardiovascular interventions</title>
<title level="j" type="abbreviated">Circ. Cardiovasc. interv.</title>
<idno type="ISSN">1941-7640</idno>
<imprint><date when="2012">2012</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><title level="j" type="main">Circulation. Cardiovascular interventions</title>
<title level="j" type="abbreviated">Circ. Cardiovasc. interv.</title>
<idno type="ISSN">1941-7640</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Artery</term>
<term>Complication</term>
<term>Coronary arteriography</term>
<term>Coronary heart disease</term>
<term>Hemodialysis</term>
<term>Human</term>
<term>Long term</term>
<term>Multicenter study</term>
<term>Nuclear magnetic resonance imaging</term>
<term>Optical coherence tomography</term>
<term>Preoperative</term>
<term>Prognosis</term>
<term>Restenosis</term>
<term>Stapling</term>
<term>Suturation</term>
<term>Test object</term>
<term>Three dimensional representation</term>
<term>Thrombosis</term>
<term>Ultrasound</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Thrombose</term>
<term>Cardiopathie coronaire</term>
<term>Resténose</term>
<term>Pronostic</term>
<term>Etude multicentrique</term>
<term>Homme</term>
<term>Coronarographie</term>
<term>Ultrason</term>
<term>Tomographie en cohérence optique</term>
<term>Complication</term>
<term>Représentation tridimensionnelle</term>
<term>Préopératoire</term>
<term>Suture chirurgicale</term>
<term>Hémodialyse</term>
<term>Imagerie RMN</term>
<term>Long terme</term>
<term>Fixation agrafe</term>
<term>Objet test</term>
<term>Artère</term>
<term>Compliance(volume pression)</term>
</keywords>
<keywords scheme="Wicri" type="topic" xml:lang="fr"><term>Homme</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Background-Nonserial observations have shown this bioresorbable scaffold to have no signs of area reduction at 6 months and recovery of vasomotion at 1 year. Serial observations at 6 months and 2 years have to confirm the absence of late restenosis or unfavorable imaging outcomes. Methods and Results-The ABSORB trial is a multicenter single-arm trial assessing the safety and performance of an everolimus-eluting bioresorbable vascular scaffold. Forty-five patients underwent serial invasive imaging, such as quantitative coronary angiography, intravascular ultrasound, and optical coherence tomography at 6 and 24 months of follow-up. From 6 to 24 months, late luminal loss increased from 0.16±0.18 to 0.27±0.20 mm on quantitative coronary angiography, with an increase in neointima of 0.68±0.43 mm<sup>2</sup>
 on optical coherence tomography and 0.17±0.26 mm<sup>2</sup>
 on intravascular ultrasound. Struts still recognizable on optical coherence tomography at 2 years showed 99% of neointimal coverage with optical and ultrasonic signs of bioresorption accompanied by increase in mean scaffold area compared with baseline (0.54±1.09 mm<sup>2</sup>
 on intravascular ultrasound, P=0.003 and 0.77±1.33 m<sup>2</sup>
 on optical coherence tomography, P=0.016). Two-year major adverse cardiac event rate was 6.8% without any scaffold thrombosis. Conclusions-This serial analysis of the second generation of the everolimus-eluting bioresorbable vascular scaffold confirmed, at medium term, the safety and efficacy of the new device.</div>
</front>
</TEI>
<inist><standard h6="B"><pA><fA01 i1="01" i2="1"><s0>1941-7640</s0>
</fA01>
<fA03 i2="1"><s0>Circ. Cardiovasc. interv.</s0>
</fA03>
<fA05><s2>5</s2>
</fA05>
<fA06><s2>5</s2>
</fA06>
<fA08 i1="01" i2="1" l="ENG"><s1>First Serial Assessment at 6 Months and 2 Years of the Second Generation of Absorb Everolimus-Eluting Bioresorbable Vascular Scaffold: A Multi-Imaging Modality Study</s1>
</fA08>
<fA11 i1="01" i2="1"><s1>ORMISTON (John A.)</s1>
</fA11>
<fA11 i1="02" i2="1"><s1>SERRUYS (Patrick W.)</s1>
</fA11>
<fA11 i1="03" i2="1"><s1>ONUMA (Yoshinobu)</s1>
</fA11>
<fA11 i1="04" i2="1"><s1>GEUNS (Robert-Jan Van)</s1>
</fA11>
<fA11 i1="05" i2="1"><s1>DE BRUYNE (Bernard)</s1>
</fA11>
<fA11 i1="06" i2="1"><s1>DUDEK (Dariusz)</s1>
</fA11>
<fA11 i1="07" i2="1"><s1>THUESEN (Leif)</s1>
</fA11>
<fA11 i1="08" i2="1"><s1>SMITS (Pieter C.)</s1>
</fA11>
<fA11 i1="09" i2="1"><s1>CHEVALIER (Bernard)</s1>
</fA11>
<fA11 i1="10" i2="1"><s1>MCCLEAN (Dougal)</s1>
</fA11>
<fA11 i1="11" i2="1"><s1>KOOLEN (Jacques)</s1>
</fA11>
<fA11 i1="12" i2="1"><s1>WINDECKER (Stephan)</s1>
</fA11>
<fA11 i1="13" i2="1"><s1>WHITBOURN (Robert)</s1>
</fA11>
<fA11 i1="14" i2="1"><s1>MEREDITH (Ian)</s1>
</fA11>
<fA11 i1="15" i2="1"><s1>DORANGE (Cecile)</s1>
</fA11>
<fA11 i1="16" i2="1"><s1>VELDHOF (Susan)</s1>
</fA11>
<fA11 i1="17" i2="1"><s1>MIQUEL HEBERT (Karine)</s1>
</fA11>
<fA11 i1="18" i2="1"><s1>RAPOZA (Richard)</s1>
</fA11>
<fA11 i1="19" i2="1"><s1>GARCIA-GARCIA (Hector M.)</s1>
</fA11>
<fA14 i1="01"><s1>Auckland City Hospital</s1>
<s2>Auckland</s2>
<s3>NZL</s3>
<sZ>1 aut.</sZ>
</fA14>
<fA14 i1="02"><s1>ThoraxCenter, Erasmus Medical Center</s1>
<s2>Rotterdam</s2>
<s3>NLD</s3>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
</fA14>
<fA14 i1="03"><s1>Cardiovascular Center</s1>
<s2>Aalst</s2>
<s3>BEL</s3>
<sZ>5 aut.</sZ>
</fA14>
<fA14 i1="04"><s1>Jagiellonian University</s1>
<s2>Krakow</s2>
<s3>POL</s3>
<sZ>6 aut.</sZ>
</fA14>
<fA14 i1="05"><s1>Skejby Sygehus University Hospital</s1>
<s2>Aarhus</s2>
<s3>DNK</s3>
<sZ>7 aut.</sZ>
</fA14>
<fA14 i1="06"><s1>Maasstad Hospital</s1>
<s2>Rotterdam</s2>
<s3>NLD</s3>
<sZ>8 aut.</sZ>
</fA14>
<fA14 i1="07"><s1>Institut Jacques Cartier</s1>
<s2>Massy</s2>
<s3>FRA</s3>
<sZ>9 aut.</sZ>
</fA14>
<fA14 i1="08"><s1>Christchurch Hospital</s1>
<s2>Christchurch</s2>
<s3>NZL</s3>
<sZ>10 aut.</sZ>
</fA14>
<fA14 i1="09"><s1>Catharina Hospital</s1>
<s2>Eindhoven</s2>
<s3>NLD</s3>
<sZ>11 aut.</sZ>
</fA14>
<fA14 i1="10"><s1>Bern University Hospital</s1>
<s2>Bern</s2>
<s3>CHE</s3>
<sZ>12 aut.</sZ>
</fA14>
<fA14 i1="11"><s1>St Vincent's Hospital</s1>
<s2>Fitzroy</s2>
<s3>AUS</s3>
<sZ>13 aut.</sZ>
</fA14>
<fA14 i1="12"><s1>Monash Cardiovascular Research Centre</s1>
<s2>Melbourne</s2>
<s3>AUS</s3>
<sZ>14 aut.</sZ>
</fA14>
<fA14 i1="13"><s1>Abbott Vascular</s1>
<s2>Diegem</s2>
<s3>BEL</s3>
<sZ>15 aut.</sZ>
<sZ>16 aut.</sZ>
<sZ>17 aut.</sZ>
</fA14>
<fA14 i1="14"><s1>Abbott Vascular</s1>
<s2>Santa Clara, CA</s2>
<s3>USA</s3>
<sZ>18 aut.</sZ>
</fA14>
<fA14 i1="15"><s1>Cardialysis</s1>
<s2>Rotterdam</s2>
<s3>NLD</s3>
<sZ>19 aut.</sZ>
</fA14>
<fA20><s1>620-632</s1>
</fA20>
<fA21><s1>2012</s1>
</fA21>
<fA23 i1="01"><s0>ENG</s0>
</fA23>
<fA43 i1="01"><s1>INIST</s1>
<s2>28045</s2>
<s5>354000502078030020</s5>
</fA43>
<fA44><s0>0000</s0>
<s1>© 2012 INIST-CNRS. All rights reserved.</s1>
</fA44>
<fA45><s0>45 ref.</s0>
</fA45>
<fA47 i1="01" i2="1"><s0>12-0423421</s0>
</fA47>
<fA60><s1>P</s1>
</fA60>
<fA61><s0>A</s0>
</fA61>
<fA64 i1="01" i2="1"><s0>Circulation. Cardiovascular interventions</s0>
</fA64>
<fA66 i1="01"><s0>USA</s0>
</fA66>
<fC01 i1="01" l="ENG"><s0>Background-Nonserial observations have shown this bioresorbable scaffold to have no signs of area reduction at 6 months and recovery of vasomotion at 1 year. Serial observations at 6 months and 2 years have to confirm the absence of late restenosis or unfavorable imaging outcomes. Methods and Results-The ABSORB trial is a multicenter single-arm trial assessing the safety and performance of an everolimus-eluting bioresorbable vascular scaffold. Forty-five patients underwent serial invasive imaging, such as quantitative coronary angiography, intravascular ultrasound, and optical coherence tomography at 6 and 24 months of follow-up. From 6 to 24 months, late luminal loss increased from 0.16±0.18 to 0.27±0.20 mm on quantitative coronary angiography, with an increase in neointima of 0.68±0.43 mm<sup>2</sup>
 on optical coherence tomography and 0.17±0.26 mm<sup>2</sup>
 on intravascular ultrasound. Struts still recognizable on optical coherence tomography at 2 years showed 99% of neointimal coverage with optical and ultrasonic signs of bioresorption accompanied by increase in mean scaffold area compared with baseline (0.54±1.09 mm<sup>2</sup>
 on intravascular ultrasound, P=0.003 and 0.77±1.33 m<sup>2</sup>
 on optical coherence tomography, P=0.016). Two-year major adverse cardiac event rate was 6.8% without any scaffold thrombosis. Conclusions-This serial analysis of the second generation of the everolimus-eluting bioresorbable vascular scaffold confirmed, at medium term, the safety and efficacy of the new device.</s0>
</fC01>
<fC02 i1="01" i2="X"><s0>002B25F</s0>
</fC02>
<fC02 i1="02" i2="X"><s0>002B27B03</s0>
</fC02>
<fC02 i1="03" i2="X"><s0>002B25G03</s0>
</fC02>
<fC03 i1="01" i2="X" l="FRE"><s0>Thrombose</s0>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="ENG"><s0>Thrombosis</s0>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="SPA"><s0>Trombosis</s0>
<s5>01</s5>
</fC03>
<fC03 i1="02" i2="X" l="FRE"><s0>Cardiopathie coronaire</s0>
<s5>02</s5>
</fC03>
<fC03 i1="02" i2="X" l="ENG"><s0>Coronary heart disease</s0>
<s5>02</s5>
</fC03>
<fC03 i1="02" i2="X" l="SPA"><s0>Cardiopatía coronaria</s0>
<s5>02</s5>
</fC03>
<fC03 i1="03" i2="X" l="FRE"><s0>Resténose</s0>
<s5>09</s5>
</fC03>
<fC03 i1="03" i2="X" l="ENG"><s0>Restenosis</s0>
<s5>09</s5>
</fC03>
<fC03 i1="03" i2="X" l="SPA"><s0>Reestenosis</s0>
<s5>09</s5>
</fC03>
<fC03 i1="04" i2="X" l="FRE"><s0>Pronostic</s0>
<s5>10</s5>
</fC03>
<fC03 i1="04" i2="X" l="ENG"><s0>Prognosis</s0>
<s5>10</s5>
</fC03>
<fC03 i1="04" i2="X" l="SPA"><s0>Pronóstico</s0>
<s5>10</s5>
</fC03>
<fC03 i1="05" i2="X" l="FRE"><s0>Etude multicentrique</s0>
<s5>11</s5>
</fC03>
<fC03 i1="05" i2="X" l="ENG"><s0>Multicenter study</s0>
<s5>11</s5>
</fC03>
<fC03 i1="05" i2="X" l="SPA"><s0>Estudio multicéntrico</s0>
<s5>11</s5>
</fC03>
<fC03 i1="06" i2="X" l="FRE"><s0>Homme</s0>
<s5>12</s5>
</fC03>
<fC03 i1="06" i2="X" l="ENG"><s0>Human</s0>
<s5>12</s5>
</fC03>
<fC03 i1="06" i2="X" l="SPA"><s0>Hombre</s0>
<s5>12</s5>
</fC03>
<fC03 i1="07" i2="X" l="FRE"><s0>Coronarographie</s0>
<s5>13</s5>
</fC03>
<fC03 i1="07" i2="X" l="ENG"><s0>Coronary arteriography</s0>
<s5>13</s5>
</fC03>
<fC03 i1="07" i2="X" l="SPA"><s0>Coronarografía</s0>
<s5>13</s5>
</fC03>
<fC03 i1="08" i2="X" l="FRE"><s0>Ultrason</s0>
<s5>14</s5>
</fC03>
<fC03 i1="08" i2="X" l="ENG"><s0>Ultrasound</s0>
<s5>14</s5>
</fC03>
<fC03 i1="08" i2="X" l="SPA"><s0>Ultrasonido</s0>
<s5>14</s5>
</fC03>
<fC03 i1="09" i2="X" l="FRE"><s0>Tomographie en cohérence optique</s0>
<s5>15</s5>
</fC03>
<fC03 i1="09" i2="X" l="ENG"><s0>Optical coherence tomography</s0>
<s5>15</s5>
</fC03>
<fC03 i1="09" i2="X" l="SPA"><s0>Tomógrafo óptico de coherencia</s0>
<s5>15</s5>
</fC03>
<fC03 i1="10" i2="X" l="FRE"><s0>Complication</s0>
<s5>16</s5>
</fC03>
<fC03 i1="10" i2="X" l="ENG"><s0>Complication</s0>
<s5>16</s5>
</fC03>
<fC03 i1="10" i2="X" l="SPA"><s0>Complicación</s0>
<s5>16</s5>
</fC03>
<fC03 i1="11" i2="X" l="FRE"><s0>Représentation tridimensionnelle</s0>
<s5>17</s5>
</fC03>
<fC03 i1="11" i2="X" l="ENG"><s0>Three dimensional representation</s0>
<s5>17</s5>
</fC03>
<fC03 i1="11" i2="X" l="SPA"><s0>Representación tridimensional</s0>
<s5>17</s5>
</fC03>
<fC03 i1="12" i2="X" l="FRE"><s0>Préopératoire</s0>
<s5>18</s5>
</fC03>
<fC03 i1="12" i2="X" l="ENG"><s0>Preoperative</s0>
<s5>18</s5>
</fC03>
<fC03 i1="12" i2="X" l="SPA"><s0>Preoperatorio</s0>
<s5>18</s5>
</fC03>
<fC03 i1="13" i2="X" l="FRE"><s0>Suture chirurgicale</s0>
<s5>19</s5>
</fC03>
<fC03 i1="13" i2="X" l="ENG"><s0>Suturation</s0>
<s5>19</s5>
</fC03>
<fC03 i1="13" i2="X" l="SPA"><s0>Sutura quirúrgica</s0>
<s5>19</s5>
</fC03>
<fC03 i1="14" i2="X" l="FRE"><s0>Hémodialyse</s0>
<s5>20</s5>
</fC03>
<fC03 i1="14" i2="X" l="ENG"><s0>Hemodialysis</s0>
<s5>20</s5>
</fC03>
<fC03 i1="14" i2="X" l="SPA"><s0>Hemodiálisis</s0>
<s5>20</s5>
</fC03>
<fC03 i1="15" i2="X" l="FRE"><s0>Imagerie RMN</s0>
<s5>21</s5>
</fC03>
<fC03 i1="15" i2="X" l="ENG"><s0>Nuclear magnetic resonance imaging</s0>
<s5>21</s5>
</fC03>
<fC03 i1="15" i2="X" l="SPA"><s0>Imaginería RMN</s0>
<s5>21</s5>
</fC03>
<fC03 i1="16" i2="X" l="FRE"><s0>Long terme</s0>
<s5>22</s5>
</fC03>
<fC03 i1="16" i2="X" l="ENG"><s0>Long term</s0>
<s5>22</s5>
</fC03>
<fC03 i1="16" i2="X" l="SPA"><s0>Largo plazo</s0>
<s5>22</s5>
</fC03>
<fC03 i1="17" i2="X" l="FRE"><s0>Fixation agrafe</s0>
<s5>23</s5>
</fC03>
<fC03 i1="17" i2="X" l="ENG"><s0>Stapling</s0>
<s5>23</s5>
</fC03>
<fC03 i1="17" i2="X" l="SPA"><s0>Fijación con grapa</s0>
<s5>23</s5>
</fC03>
<fC03 i1="18" i2="X" l="FRE"><s0>Objet test</s0>
<s5>24</s5>
</fC03>
<fC03 i1="18" i2="X" l="ENG"><s0>Test object</s0>
<s5>24</s5>
</fC03>
<fC03 i1="18" i2="X" l="SPA"><s0>Objeto prueba</s0>
<s5>24</s5>
</fC03>
<fC03 i1="19" i2="X" l="FRE"><s0>Artère</s0>
<s5>25</s5>
</fC03>
<fC03 i1="19" i2="X" l="ENG"><s0>Artery</s0>
<s5>25</s5>
</fC03>
<fC03 i1="19" i2="X" l="SPA"><s0>Arteria</s0>
<s5>25</s5>
</fC03>
<fC03 i1="20" i2="X" l="FRE"><s0>Compliance(volume pression)</s0>
<s4>INC</s4>
<s5>86</s5>
</fC03>
<fC07 i1="01" i2="X" l="FRE"><s0>Pathologie de l'appareil circulatoire</s0>
<s5>37</s5>
</fC07>
<fC07 i1="01" i2="X" l="ENG"><s0>Cardiovascular disease</s0>
<s5>37</s5>
</fC07>
<fC07 i1="01" i2="X" l="SPA"><s0>Aparato circulatorio patología</s0>
<s5>37</s5>
</fC07>
<fC07 i1="02" i2="X" l="FRE"><s0>Pathologie des vaisseaux sanguins</s0>
<s5>38</s5>
</fC07>
<fC07 i1="02" i2="X" l="ENG"><s0>Vascular disease</s0>
<s5>38</s5>
</fC07>
<fC07 i1="02" i2="X" l="SPA"><s0>Vaso sanguíneo patología</s0>
<s5>38</s5>
</fC07>
<fN21><s1>331</s1>
</fN21>
<fN44 i1="01"><s1>OTO</s1>
</fN44>
<fN82><s1>OTO</s1>
</fN82>
</pA>
</standard>
</inist>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Asie/explor/AustralieFrV1/Data/PascalFrancis/Curation

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 005012 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/PascalFrancis/Curation/biblio.hfd -nk 005012 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Asie
   |area=    AustralieFrV1
   |flux=    PascalFrancis
   |étape=   Curation
   |type=    RBID
   |clé=     Pascal:12-0423421
   |texte=   First Serial Assessment at 6 Months and 2 Years of the Second Generation of Absorb Everolimus-Eluting Bioresorbable Vascular Scaffold: A Multi-Imaging Modality Study
}}

This area was generated with Dilib version V0.6.33.
Data generation: Tue Dec 5 10:43:12 2017. Site generation: Tue Mar 5 14:07:20 2024

	Serveur d'exploration sur les relations entre la France et l'Australie
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Serveur d'exploration sur les relations entre la France et l'Australie

First Serial Assessment at 6 Months and 2 Years of the Second Generation of Absorb Everolimus-Eluting Bioresorbable Vascular Scaffold: A Multi-Imaging Modality Study

First Serial Assessment at 6 Months and 2 Years of the Second Generation of Absorb Everolimus-Eluting Bioresorbable Vascular Scaffold: A Multi-Imaging Modality Study

Source :

Descripteurs français

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri